Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared an article Minjung Bak and colleagues authored on X:
“Cardiotoxicity of osimertinib is real. In this Korean study, osimertinib-related cardiotoxicity was 4.7%, including 3.4% requiring cardiologic intervention. Age and previous heart conditions identified. Implications for long-lasting treatment.”
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population
Authors: Minjung Bak et al.
